Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia.
Fiche publication
Date publication
décembre 2020
Journal
Clinical case reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DELMER Alain
Tous les auteurs :
Gauchy AC, Hentzien M, Wynckel A, de Marcellus V, Rodier C, Delmer A, Quinquenel A
Lien Pubmed
Résumé
Eculizumab may be considered as an emergency therapeutic option in refractory life-threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.
Mots clés
chronic myelomonocytic leukemia, eculizumab, warm autoimmune hemolytic anemia
Référence
Clin Case Rep. 2020 Dec;8(12):2641-2644